Table 1.
All subjects |
Amiloride–HCTZ |
HCTZ–Amiloride |
||||
---|---|---|---|---|---|---|
N | % | n | % | n | % | |
Females | 5 | 55.6 | 4 | 80.0 | 1 | 25.0 |
Caucasian | 4 | 44.4 | 2 | 40.0 | 2 | 50.0 |
Asian | 1 | 11.1 | 0 | 0.0 | 1 | 25.0 |
Hispanic | 5 | 55.6 | 4 | 80.0 | 1 | 25.0 |
Mean | SD | Mean | SD | Mean | SD | |
---|---|---|---|---|---|---|
Age (yr) | 58.4 | 10.0 | 56.4 | 13.2 | 61.0 | 4.3 |
BMI (kg/m2) | 32.2 | 6.2 | 28.3 | 2.5 | 37.1 | 6.1 |
Albumin/Creatinine (mg/g) | 1120 | 780 | 1070 | 650 | 1170 | 1030 |
Weight (kg) | 84.0 | 21.3 | 68.7 | 7.6 | 103.1 | 16.1 |
Creatinine (mg/dl) | 0.8 | 0.3 | 0.7 | 0.2 | 1.0 | 0.2 |
Potassium (mmol/l) | 4.4 | 0.4 | 4.2 | 0.4 | 4.6 | 0.2 |
Mean SBP (mm Hg) | 132 | 13 | 123 | 20 | 126 | 19 |
Mean DBP (mm Hg) | 80.3 | 8.1 | 75.1 | 3.9 | 75.0 | 11.3 |
eGFR (ml/min) | 87.4 | 20.4 | 92.6 | 23.0 | 77.4 | 14.8 |
Of the 9 participants in the trial, 5 were randomized to amiloride followed by HCTZ (Amiloride – HCTZ) and 4 were randomized to HCTZ followed by amiloride (HCTZ – Amiloride).
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure.